en · de · es · fr · pt
peptide-index.peptides7501.com › Info › Mechanism And Preclinical Findings — Common Mistakes

Mechanism And Preclinical Findings — Common Mistakes

By Editorial Desk · published 2025-09-03 · last reviewed 2025-10-04 · Info

This is a working overview of freeze-thaw, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2025-10-04 and is reviewed periodically as new material appears.

Mechanism and Preclinical Findings

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

Analytical and Handling Considerations

Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.

SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall molecule; not a steroid or peptide.
Primary targetsNR1D1 and NR1D2Also known as REV-ERBα and REV-ERBβ.
Studied routesIntraperitoneal in rodentsOral bioavailability in humans is not established.
Human approvalNo approved therapeutic indicationNo recognized clinical use.
Key uncertaintyHuman physiological effectsPreclinical findings may not translate.

Regulation, Testing, and Storage

SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.

Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.

Related pages on this site

Analytical Detection and Regulatory Status

Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.

Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.

Handling, Analysis, and Regulation

Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.

Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.

Supporting material

One way to effectively deal with the inherent multi-physics and the control systems development that is involved when including intelligent systems, is to adopt the V-Model approach to systems development, as has been widely used in the automotive industry for twenty years or more. In this V-approach, system-level requirements are propagated down the V via subsystems to component design, and the system performance is validated at increasing integration levels. Engineering of mechatronic systems requires the application of two interconnected "V-cycles": one focusing on the multi-physics system engineering (like the mechanical and electrical components of an electrically powered steering system, including sensors and actuators); and the other focuses on the controls engineering, the control logic, the software and realization of the control hardware and embedded software.

=== Names === Vortioxetine was previously sold under the brand name Brintellix in the United States, but in May 2016, the US Food and Drug Administration (FDA) approved a name change to Trintellix in order to avoid confusion with the blood-thinning medication Brilinta (ticagrelor). Other brand names include Torvox, Vantaxa, Voxigain, Trivoxetin, Vipca, Vortica, Vatoin, Xomat, Vortidif.

Much of the "medicinal" use of equid milk (donkey and mare) is based on tradition. Scientific studies on equid milk are often lacking regarding the beneficial effects for certain pathologies. Popular medicine or traditional medicine is defined as one that follows traditions or practices before the advent of industrial medicine. Many of these practices have become rooted in popular knowledge and tradition. The first written documents reporting the nutritional and "curative" effects of equine milk date back to around 2000 years ago. Herodotus in the 5th century BC mentions it as a nutritious drink. Hippocrates (460–370 BC), the father of medicine, described the medicinal virtues of donkey milk. He prescribed donkey milk for numerous ailments, such as liver problems, edemas, nosebleeds, poisonings, infectious diseases, the healing of sores, and fevers. In Roman times, donkey milk was used as a universal remedy. Pliny the Elder (23–79 AD), in his encyclopedic work Naturalis Historia, described its many health benefits, ranging from its use as an anti-venom or as a relief for external irritations (itching) to the use of it in a pomade (ointment) for the eyes. He states that donkey milk is the most effective as a medicine, followed by cow's milk, and then goat's milk. During the Renaissance, donkey milk was the subject of the first real scientific consideration when Francis I, king of France, on the advice of his doctors, used donkey milk to recover from a long illness. There are many testimonials on the effectiveness of donkey milk.

Sources: en.wikipedia.org

Supporting material

== Diagnosis == Protein function tests that demonstrate a reduce in chorein levels and also genetic analysis can confirm the diagnosis given to a patient. For a disease like this it is often necessary to sample the blood of the patient on multiple occasions with a specific request given to the haematologist to examine the film for acanthocytes. Another point is that the diagnosis of the disease can be confirmed by the absence of chorein in the western blot of the erythrocyte membranes.

Vosilasarm, also known by the development codes RAD140 and EP0062 and by the black-market name Testolone or Testalone, is a selective androgen receptor modulator (SARM) which is under development for the treatment of hormone-sensitive breast cancer. It is specifically under development for the treatment of androgen receptor-positive, estrogen receptor-negative, HER2-negative advanced breast cancer. Vosilasarm was also previously under development for the treatment of sarcopenia (age-related muscle atrophy), osteoporosis, and weight loss due to cancer cachexia, but development for these indications was discontinued. The drug is taken by mouth. Side effects of vosilasarm may include vomiting, dehydration, constipation, decreased appetite, weight loss, changes in sex hormone levels, elevated liver enzymes, and liver toxicity. Vosilasarm is a nonsteroidal SARM, acting as an agonist of the androgen receptor (AR), the biological target of androgens and anabolic steroids like testosterone and dihydrotestosterone (DHT). However, it shows dissociation of effect between tissues in preclinical studies, with agonistic and anabolic effects in muscle, agonistic effects in breast, and partially agonistic or antagonistic effects in the prostate gland and seminal vesicles. Vosilasarm was developed in 2010 and was first described in the literature in 2011. It was originally developed by Radius Health and is now under development by Ellipses Pharma.

No chronology will be observed here, nor is one necessary. Hence each reader will put together the book for himself, as in a game of dominoes or cards, and, as with a mirror, he will get out of this dictionary as much as he puts into it, for you [...] cannot get more out of the truth than what you put into it. The book comes in two different editions, one "male" and one "female", which differ in only a critical passage in a single paragraph. In 1984, Pavić stated that the Khazars were a metaphor for a small people surviving in between great powers and great religions. In Yugoslavia, Pavić stated five years later, Serbs recognized their own fate; it was the same in Slovenia and elsewhere, a schoolbook on survival. The same in Hungary and Czechoslovakia, and on and on. A French critic said, 'We are all Khazars in the age of nuclear threat and poisoned environment.' A ballet adaption of the Dictionary of the Khazars was staged at Madlenianum Opera and Theatre. A play based on the novel has also been staged in the New Riga Theatre.

Sources: en.wikipedia.org

Supporting material

According to the Panel of Experts on Yemen established pursuant to Security Council resolution 2140, the Houthis have carried out a wide range of human rights violations, including violations of international humanitarian law and abuse of women and children. Children as young as 13 have been arrested for "indecent acts" for alleged homosexual orientation or "political cases" when their families do not comply with Houthi ideology or regulations. Minors share cells with adult prisoners, and according to unspecified reports that the Panel has deemed "credible", boys held in Al-Shahid Al-Ahmar police station in Sana'a are systematically raped. Aside from the Panel of Experts, London-based Arabic newspaper Asharq Al-Awsat alleges that the Houthis have revived slavery in Yemen.

=== Quality === In the context of a clinical trial, quality typically refers to the absence of errors which can impact decision making, both during the conduct of the trial and in use of the trial results.

Organic chemists use the tools of thermodynamics to study the bonding, stability, and energetics of chemical systems. This includes experiments to measure or determine the enthalpy (ΔH), entropy (ΔS), and Gibbs' free energy (ΔG) of a reaction, transformation, or isomerization. Chemists may use various chemical and mathematical analyses, such as a Van 't Hoff plot, to calculate these values. Empirical constants such as bond dissociation energy, standard heat of formation (ΔfH°), and heat of combustion (ΔcH°) are used to predict the stability of molecules and the change in enthalpy (ΔH) through the course of the reactions. For complex molecules, a ΔfH° value may not be available but can be estimated using molecular fragments with known heats of formation. This type of analysis is often referred to as Benson group increment theory, after chemist Sidney Benson who spent a career developing the concept. The thermochemistry of reactive intermediates—carbocations, carbanions, and radicals—is also of interest to physical organic chemists. Group increment data are available for radical systems. Carbocation and carbanion stabilities can be assessed using hydride ion affinities and pKa values, respectively.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.

How does SR9009 differ from typical receptor agonists?

REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.

Has SR9009 been tested in humans?

Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.

How is SR9009 detected in laboratory samples?

Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.

Network